Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 1
2006 pubmed

Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction.

Chen. Min M; Aprahamian. Charles J CJ; Celik. Ahmet A; Georgeson. Keith E KE; Garvey. W Timothy WT; Harmon. Carroll M CM; Yang. Yingkui Y

Key Findings

  • Changing E131, D154, D158, or H298 reduces peptide binding and signaling
  • Replacing D121 or D332 stops binding and receptor activity completely
  • Altering L165 switches an antagonist into an agonist

Practical Outcomes

  • The findings mainly help drug developers understand how MC3R works; they don’t give direct dosing or usage advice for melanotan‑I, so biohackers have little immediate to apply.

Summary

Scientists changed specific parts of the MC3R protein to see which spots are needed for the peptide NDP‑MSH to bind and activate the receptor. They found several key amino acids that are essential for binding, signaling, and whether a molecule acts as an agonist or antagonist.

Abstract

Melanocortin-3 receptor (MC3R), primarily expressed in the hypothalamus, plays an important role in the regulation of energy homeostasis. MC3R-deficient (MC3R(-)(/)(-)) mice demonstrate increased fat mass, higher feeding efficiency, hyperleptinaemia, and mild hyperinsulinism. At least one specific mutation of MC3R has been identified to be associated with human obesity. Functional analysis of this altered MC3R (I183N) has indicated that the mutation completely abolishes agonist-mediated receptor activation. However, the specific molecular determinants of MC3R responsible for ligand binding and receptor signaling are currently unknown. The present study is to determine the structural aspects of MC3R responsible for ligand binding and receptor signaling. On the basis of our theoretical model for MC1R, using mutagenesis, we have examined 19 transmembrane domain amino acids selected for these potential roles in ligand binding and receptor signaling. Our results indicate that (i) substitutions of charged amino acid residues E131 in transmembrane domain 2 (TM2), D154 and D158 in TM3, and H298 in TM6 with alanine dramatically reduced NDP-MSH binding affinity and receptor signaling, (ii) substitutions of aromatic amino acids F295 and F296 in TM6 with alanine also significantly decreased NDP-MSH binding and receptor activity, (iii) substitutions of D121in TM2 and D332 in TM7 with alanine resulted in the complete loss of ligand binding, ligand induced receptor activation, and cell surface protein expression, and (iv) interestingly, substitution of L165 in TM3 with methionine or alanine switched antagonist SHU9119 into a receptor agonist. Our results suggest that TM3 and TM6 are important for NDP-MSH binding, while D121 in TM2 and D332 in TM7 are crucial for receptor activity and signaling. Importantly, L165 in TM3 is critical for agonist or antagonist selectivity. These results provide important information about the molecular determinants of hMC3R responsible for ligand binding and receptor signaling.

Study Information

Provider

pubmed

Year

2006

Date

2006-01-31T00:00:00.000Z

DOI

10.1021/bi0521792